Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.66 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566229 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14199627 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3498224 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14178408 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL42134 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL18660222 | 0.90 | P2RY6 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12988228 | 0.89 | SLC28A1 (0.67) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12259056 | 0.88 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL121732 | 0.88 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL1532521 | 0.87 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | SLC28A1 1196/4885SLC28A2 1598/4885SLC29A1 648/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | SLC28A1 1372/4885SLC28A2 1639/4885SLC29A1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.